Vishal Jhanji is an Ophthalmology physician affiliated with UPMC Health System. OpenAlex indexes 633 publications with 12,341 citations (h-index 55); ClinicalTrials.gov lists 3 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Ophthalmology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- PXL-Platinum 330 in Eyes With Corneal Thinning Conditions
Sponsor: Vishal Jhanji
- Tear Film Markers in Dry Eye Syndrome
Sponsor: Vishal Jhanji
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
10 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
63.6%Corticosteroid49.5%Prednisolone Acetate60%Fluorometholone41%Part D≥133 patientsalpha-Adrenergic Agonist6.5%Brimonidine Tartrate-Timolol52%Brimonidine Tartrate48%Part D<11 patients+ 3 more classes in this area
Anti-infectives
24.9%Fluoroquinolone Antibacterial12.3%Moxifloxacin100%Part D≥49 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor5.6%Valacyclovir100%Part D≥17 patients+ 2 more classes in this area
Cancer & immunology
6.3%Calcineurin inhibitor6.3%Restasis61%Cyclosporine39%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Optimized Artificial Intelligence for Enhanced Ectasia Detection Using Scheimpflug-Based Corneal Tomography and Biomechanical Data
American Journal of Ophthalmology
2022 - Categorization of Marketed Artificial Tear Formulations Based on Their Ingredients: A Rational Approach for Their Use
Journal of Clinical Medicine
2021 - Paradox of complex diversity: Challenges in the diagnosis and management of bacterial keratitis
Progress in Retinal and Eye Research
2021 - Biomaterials for corneal endothelial cell culture and tissue engineering
Journal of Tissue Engineering
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Robyn Domsic
UPMC Health System
Carolyn Willis
UPMC Health System
Devereux Saller
UPMC Health System
Richard Redlinger, MD
UPMC Health System
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Richard Spaide, MD
Vitreous Retina Macula Consultants of New York
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”